Literature DB >> 20159001

Visfatin and retinol-binding protein 4 concentrations in lean, glucose-tolerant women with PCOS.

Bulent O Yildiz1, Gurkan Bozdag, Umit Otegen, Ayla Harmanci, Kubra Boynukalin, Zehra Vural, Serafettin Kirazli, Hakan Yarali.   

Abstract

Since insulin resistance is accepted to be a common feature of polycystic ovary syndrome (PCOS), the exact molecular mechanism(s) involved in glucose and lipid metabolism have been under investigation in the syndrome. Recently, two novel adipokines, namely visfatin and retinol-binding protein 4 (RBP4), have been suggested to play a role in insulin resistance and diabetes. This study sought to determine whether plasma concentrations of visfatin and RBP4 are altered in PCOS by comparing a total of 27 lean, normal glucose-tolerant PCOS patients with 19 age- and body mass index-matched healthy controls. The mean plasma visfatin concentrations were higher in PCOS patients than those in healthy subjects (37.9+/-18.2 versus 19.8+/-17.5, P<0.01), while RBP4 concentrations were similar between the two. Both adipokines were correlated with each other in the whole (r=0.50, P<0.01) and in PCOS (r=0.52, P<0.01) groups but not in controls. The results suggest that lean, glucose-tolerant women with PCOS have increased circulating visfatin and unaltered RBP4 concentrations compared with healthy lean women. In order to clarify overlapping effects and their potential contribution to the pathophysiology of PCOS, further studies are needed. Copyright (c) 2009 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20159001     DOI: 10.1016/j.rbmo.2009.10.016

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  7 in total

1.  Retinol-binding protein 4 correlates with triglycerides but not insulin resistance in prepubertal children with and without premature adrenarche.

Authors:  Aviva B Sopher; Adrienne T Gerken; Eun-Ju Lee; William E Blaner; Stefanie Deeds; Dympna Gallagher; Dikoma C Shungu; Xiangling Mao; Abeer Hassoun; Donald J Mc Mahon; Sharon E Oberfield
Journal:  J Pediatr Endocrinol Metab       Date:  2011       Impact factor: 1.634

2.  Metabolic manifestations of polycystic ovary syndrome in nonobese adolescents: retinol-binding protein 4 and ectopic fat deposition.

Authors:  Aviva B Sopher; Adrienne T Gerken; William S Blaner; Jeremy M Root; Donald J McMahon; Sharon E Oberfield
Journal:  Fertil Steril       Date:  2012-02-17       Impact factor: 7.329

3.  Retinol-binding protein 4 is elevated and is associated with free testosterone and TSH in postmenopausal women.

Authors:  N Güdücü; U Görmüş; Z N Kavak; H İşçi; A B Yiğiter; İ Dünder
Journal:  J Endocrinol Invest       Date:  2013-04-30       Impact factor: 4.256

4.  Serum visfatin levels in non-obese women with polycystic ovary syndrome and matched controls.

Authors:  Jin Ju Kim; Young Min Choi; Min A Hong; Min Jeong Kim; Soo Jin Chae; Sun Mie Kim; Kyu Ri Hwang; Sang Ho Yoon; Seung Yup Ku; Chang Suk Suh; Seok Hyun Kim
Journal:  Obstet Gynecol Sci       Date:  2018-02-05

5.  Assessment of FSHR, AMH, and AMHRII variants in women with polycystic ovary syndrome.

Authors:  Ewa Czeczuga-Semeniuk; Katarzyna Jarząbek; Marzenna Galar; Piotr Kozłowski; Nela A Sarosiek; Gabriela Zapolska; Sławomir Wołczyński
Journal:  Endocrine       Date:  2014-07-11       Impact factor: 3.633

6.  Plasma visfatin levels and mRNA expression of visfatin in peripheral blood mononuclear cells and peripheral blood monocyte-derived macrophages from normal weight females with polycystic ovary syndrome.

Authors:  Jing Zhang; Lingling Zhou; Liulin Tang; Liangzhi Xu
Journal:  Exp Ther Med       Date:  2014-02-18       Impact factor: 2.447

7.  Serum retinol-binding protein 4 levels in polycystic ovary syndrome.

Authors:  Shilpa Lingaiah; Laure Morin-Papunen; Terhi Piltonen; Inger Sundström-Poromaa; Elisabet Stener-Victorin; Juha S Tapanainen
Journal:  Endocr Connect       Date:  2019-06-01       Impact factor: 3.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.